Share on StockTwits

Meridian Bioscience Inc. (NASDAQ:VIVO) updated its FY14 earnings guidance on Tuesday. The company provided earnings per share guidance of $0.85-0.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.86, Analyst Ratings Network reports. The company issued revenue guidance of $190-195 million, compared to the consensus revenue estimate of $191.59 million.Meridian Bioscience also updated its FY15 guidance to $0.85-0.91 EPS.

Meridian Bioscience Inc. (NASDAQ:VIVO) opened at 19.57 on Tuesday. Meridian Bioscience Inc. has a one year low of $19.14 and a one year high of $27.72. The stock has a 50-day moving average of $20.14 and a 200-day moving average of $20.67. The company has a market cap of $813.5 million and a P/E ratio of 23.09.

Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, July 24th. The company reported $0.21 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.22 by $0.01. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $47.96 million. During the same quarter in the prior year, the company posted $0.24 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis. On average, analysts predict that Meridian Bioscience Inc. will post $0.86 earnings per share for the current fiscal year.

Meridian Bioscience, Inc (NASDAQ:VIVO) is a fully-integrated life science company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.